FDA Approves REVTORPYK (GEDATOLISIB) for Celcuity Inc.
The FDA has approved REVTORPYK (gedatolisib) under NDA219908 for Celcuity Inc.
Published: July 18, 2026
Updated: July 18, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / PI3K Inhibitor
Asset: REVTORPYK
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
REVTORPYK
Indication
Signal assessment
Signal strength
high
Confidence level
high
Signalhigh
Confidencehigh
Why it matters
The FDA's approval of REVTORPYK (gedatolisib) is a significant milestone for Celcuity Inc., enhancing its position in the competitive oncology landscape. This approval necessitates close monitoring of market dynamics and competitive responses as the drug enters the market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market reception, sales performance, and any emerging competitive responses from other oncology therapies.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.